<?xml version="1.0" encoding="UTF-8"?>
<p id="Par214">HIV-1 leukoencephalopathy is chararcterized by (Fig. 
 <xref rid="Fig4" ref-type="fig">26.4a–j</xref>)
 <list list-type="bullet">
  <list-item>
   <p id="Par215">diffuse damage to the white matter including
    <list list-type="bullet">
     <list-item>
      <p id="Par216">myelin loss</p>
     </list-item>
     <list-item>
      <p id="Par217">reactive astrogliosis</p>
     </list-item>
     <list-item>
      <p id="Par218">macrophages</p>
     </list-item>
     <list-item>
      <p id="Par219">multinucleated giant cells</p>
     </list-item>
    </list>
   </p>
  </list-item>
  <list-item>
   <p id="Par220">Myelin pallor is usually found around the gliomesenchymal nodule containing the MGC.</p>
  </list-item>
  <list-item>
   <p id="Par221">Little or no inflammatory infiltrates are seen.</p>
  </list-item>
  <list-item>
   <p id="Par222">In the absence of multinucleated giant cells, the presence of HIV-antigen or HIV nucleic acids has to be demonstrated either by immunohistochemistry or by in situ hybridization.</p>
  </list-item>
  <list-item>
   <p id="Par223">Axonal damage can be demonstrated with immunohistochemistry for β-amyloid precursor protein.</p>
  </list-item>
  <list-item>
   <p id="Par224">HIVL usually occur in the later stages of the AIDS infection.</p>
  </list-item>
  <list-item>
   <p id="Par225">Synonyms previously used: progressive diffuse leukoencephalopathy</p>
  </list-item>
 </list>
</p>
